下肢动脉疾病与冠心病血运重建后死亡率差异
下肢动脉疾病组粗死亡率风险比为2.91(95%CI 2.54-3.34),调整年龄、性别和多血管病变后降至2.14(1.83-2.50);逐步调整合并症、药物和脆弱性后风险比进一步降至1.17(0.98-1.39),超额死亡率衰减达86%。结论认为下肢动脉疾病患者血运重建后死亡风险近乎冠心病的三倍,超额死亡很大程度上归因于基线特征差异,包括潜在可临床或社会干预的因素。
要点
- 下肢动脉疾病患者血运重建后1年死亡粗风险为冠心病患者的2.91倍(95%CI 2.54-3.34)。
- 调整年龄、性别和多血管病变后风险比降至2.14(95%CI 1.83-2.50),衰减29%。
- 进一步调整合并症、药物和脆弱性后风险比降至1.17(95%CI 0.98-1.39),衰减86%。
核心结论
- 下肢动脉疾病患者血运重建后死亡风险近乎冠心病患者的三倍,超额死亡很大程度上归因于基线特征差异,包括潜在可临床或社会干预的因素。
主要发现
- 下肢动脉疾病组较冠心病组年龄更大、多血管病变更多、合并症更多且接受心脏保护药物更少,脆弱性更常见。
- 下肢动脉疾病 vs 冠心病的粗死亡风险比为2.91(95%CI 2.54-3.34)。
- 调整年龄、性别和多血管病变后风险比降至2.14(95%CI 1.83-2.50),超额死亡率衰减29%。
- 逐步调整合并症、药物和脆弱性后风险比分别降至1.48(95%CI 1.26-1.72)、1.33(95%CI 1.12-1.58)和1.17(95%CI 0.98-1.39),衰减分别达64%、73%和86%。
临床怎么用
- 对下肢动脉疾病血运重建患者应关注基线特征差异,包括合并症、药物使用和脆弱性,以识别高风险人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Patients undergoing revascularization for lower extremity arterial disease (LEAD) may face a higher risk of mortality than those with coronary artery disease (CAD). This study aimed to characterize the difference in mortality risk between patients undergoing revascularization for LEAD and CAD and identify associated factors. METHODS: The 1-year database of 10 754 patients undergoing revascularization for CAD (n = 6349) and LEAD (n = 4405) was analysed. Poisson regression models were used to characterize interpopulation differences in mortality, adjusting for baseline clinical features, including age, sex, polyvascular disease, comorbidities, medications, and vulnerabilities. RESULTS: Individuals with LEAD were older, were more likely to have polyvascular disease, had more comorbidities, and received fewer cardioprotective drugs than those with CAD. Vulnerabilities remained more common in the LEAD group even after adjusting for these clinical features. The crude risk ratio of mortality incidence for LEAD vs. CAD was 2.91 (95% confidence interval, 2.54-3.34), attenuated to 2.14 (1.83-2.50) after controlling for age, sex, and polyvascular disease. The percentage attenuation in the excessive mortality associated with LEAD was 29%. The stepwise addition of comorbidities, medications, and vulnerabilities as adjusting factors attenuated the incidence risk ratio to 1.48 (1.26-1.72), 1.33 (1.12-1.58), and 1.17 (0.98-1.39), respectively, and increased the percentage attenuation to 64%, 73%, and 86%, respectively. CONCLUSIONS: Mortality risk was almost three-fold higher in patients undergoing revascularization for LEAD than in those with CAD. The excessive mortality was considerably attributable to inter-group differences in baseline characteristics, including potentially clinically or socially modifiable factors.
引用
- Takahara M, Soga Y, Iida O, et al. Lower extremity arterial disease vs. coronary artery disease: mortality differences after revascularization. Eur Heart J. 2024. PMID: 38693795. doi:10.1093/eurheartj/ehae207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。